Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma – STRIKE Read more
GAIN-BCG: Gemcitabine Alternating with INtravesical BCG Randomized Against BCG Alone for Patients with Recurrent High Grade Non-Muscle Invasive Bladder Cancer Read more
Prospective, Controlled Study Evaluating Potency and Continence following Robot-Assisted Radical Prostatectomy with and without Cryopreserved Umbilical Cord Allograft. Read more
Real-World Survival Among Patients with HER2-Positive and HER2-Low Metastatic Malignancies Who Received HER2-Targeting Agents Read more
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) Read more
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY Read more
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA Mutated HER2 Positive Locally Advanced or Metastatic Breast Cancer Read more
LOTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER Read more
